NRIX - Nurix Therapeutics Inc
IEX Last Trade
25.22
0.220 0.872%
Share volume: 809,668
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$25.00
0.22
0.88%
View ratios
| Fiscal Date | 2022-08-31 | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 | 2024-02-29 | 2024-05-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-10-06 | 2023-02-09 | 2023-04-13 | 2023-07-13 | 2023-10-12 | 2024-02-15 | 2024-04-10 | 2024-07-11 | |
| Assets | |||||||||
| Total Assets | 459.338 M | 416.759 M | 370.154 M | 350.624 M | 308.195 M | 355.598 M | 312.674 M | 511.031 M | |
| Current Assets | 354.871 M | 318.449 M | 288.329 M | 290.014 M | 267.949 M | 295.503 M | 250.969 M | 450.217 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 10.393 M | 9.308 M | 11.183 M | 8.837 M | 7.097 M | 7.595 M | 6.976 M | 7.078 M | |
| Short Term Investments | 10.393 M | 9.308 M | 11.183 M | 8.837 M | 7.097 M | 7.595 M | 6.976 M | 7.078 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 2.000 M | 0.000 | 0.000 | 0.000 | |
| Current Cash | 344.478 M | 309.141 M | 277.146 M | 281.177 M | 258.852 M | 287.908 M | 243.993 M | 443.139 M | |
| Total Non-current Assets | 104.467 M | 98.310 M | 81.825 M | 60.610 M | 40.246 M | 60.095 M | 61.705 M | 60.814 M | |
| Property Plant Equipment | 16.501 M | 17.163 M | 17.717 M | 18.495 M | 16.581 M | 16.808 M | 17.871 M | 18.557 M | |
| Other Assets | 17.940 M | 16.367 M | 14.758 M | 13.751 M | 12.882 M | 34.965 M | 32.641 M | 31.976 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 459.338 M | 416.759 M | 370.154 M | 350.624 M | 308.195 M | 355.598 M | 312.674 M | 511.031 M | |
| Total liabilities | 116.793 M | 113.063 M | 96.102 M | 90.703 M | 74.378 M | 155.105 M | 143.926 M | 140.338 M | |
| Total current liabilities | 67.500 M | 70.655 M | 64.878 M | 72.262 M | 61.493 M | 86.958 M | 87.623 M | 80.779 M | |
| Accounts Payable | 6.053 M | 5.064 M | 5.629 M | 4.525 M | 2.187 M | 6.401 M | 5.918 M | 2.813 M | |
| Other liabilities | 41.548 M | 35.974 M | 26.118 M | 14.683 M | 10.243 M | 45.022 M | 34.457 M | 38.674 M | |
| Current long term debt | 5.496 M | 5.530 M | 5.556 M | 5.583 M | 5.362 M | 7.489 M | 7.310 M | 7.934 M | |
| Long term debt | 7.745 M | 6.434 M | 5.106 M | 3.758 M | 2.642 M | 23.125 M | 21.846 M | 20.885 M | |
| Other liabilities | 41.548 M | 35.974 M | 26.118 M | 14.683 M | 10.243 M | 45.022 M | 34.457 M | 38.674 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 342.545 M | 303.696 M | 274.052 M | 259.921 M | 233.817 M | 200.493 M | 168.748 M | 370.693 M | |
| Common stock | 50.869 M | 53.971 M | 54.028 M | 54.259 M | 54.391 M | 54.673 M | 54.903 M | 62.378 M | |
| Retained earnings | -354.535 M | -401.252 M | -441.985 M | -466.262 M | -503.244 M | -545.200 M | -586.718 M | -631.264 M |